Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Vancomycin resistance

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    13 result(s) found for: Vancomycin resistance. Displaying page 1 of 1.
    EudraCT Number: 2015-000203-89 Sponsor Protocol Number: NeoVanc Start Date*: 2016-07-18
    Sponsor Name:Fondazione PENTA Onlus
    Full Title: Multi-centre, randomised, open label, phase IIb study to compare the efficacy, safety and pharmacokinetics (PK) of an optimised dosing to a standard dosing regimen of vancomycin in neonates and inf...
    Medical condition: Neonatal late onset sepsis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10053598 Late onset neonatal sepsis LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) IT (Prematurely Ended) EE (Prematurely Ended) ES (Prematurely Ended) GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-000244-10 Sponsor Protocol Number: EGBAB Start Date*: 2019-12-13
    Sponsor Name:Region Uppsala
    Full Title: Influence of antibiotic treatment on the normal flora and the presence of resistance genes in known carriers of ESBL and VRE
    Medical condition: Carriage of genes coding for vancomycin resistant enterococci (VRE) and extended spectrum betalactamase producing enterobacteriales (EPE) phenotypes.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002528-17 Sponsor Protocol Number: AC-061A301 Start Date*: 2014-03-14
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: A multi-center, randomized, double-blind study to compare the efficacy and safety of cadazolid versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD)
    Medical condition: Clostridium difficile-associated diarrhea (CDAD)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10054236 Clostridium difficile infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) ES (Completed) PL (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002508-15 Sponsor Protocol Number: AC-061A302 Start Date*: 2014-03-03
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: A multi-center, randomized, double-blind study to compare the efficacy and safety of cadazolid versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD)
    Medical condition: Clostridium difficile-associated diarrhea (CDAD)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10054236 Clostridium difficile infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) HU (Completed) SK (Completed) GR (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2021-001708-14 Sponsor Protocol Number: ABOGRAFT-01 Start Date*: 2021-06-29
    Sponsor Name:Region Östergötland
    Full Title: Antibiotic Impregnated Bone Graft to reduce infection in hip replacement. The ABOGRAFT trial
    Medical condition: Patients scheduled for any type of hip arthroplasty requiring bone grafting
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-002910-12 Sponsor Protocol Number: 0017 Start Date*: 2005-06-17
    Sponsor Name:Theravance Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Complicated Gram-Positive Skin and Skin Structure Infections with a focus on Pa...
    Medical condition: Complicated Gram-Positive Skin and Skin Structure Infections With a Focus on Patients With Infections Due to Methicillin-Resistant Staphylococcus aureus.
    Disease: Version SOC Term Classification Code Term Level
    7.0 10040872 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002914-12 Sponsor Protocol Number: 0018 Start Date*: 2005-04-13
    Sponsor Name:Theravance Inc.
    Full Title: A phase 3, Randomized, Double-Blind, Multinational Trial of Intravenous Televancin Versus Vancomycin for Treatment of Complicated Gram-positive Skin and Skin Structure Infections with a focus on Pa...
    Medical condition: Complicated Gram-Positive Skin and Skin Structure Infections With a Focus on Patients With Infections Due to Methicillin-Resistant Staphylococcus aureus.
    Disease: Version SOC Term Classification Code Term Level
    7.0 10040872 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003444-80 Sponsor Protocol Number: 2020-01471 Start Date*: 2020-11-17
    Sponsor Name:Sahlgrenska University Hospital
    Full Title: Evaluation of the clinical implementation of biofilm susceptibility to antibiotics using Minimum Biofilm Eradication Concentration (MBEC) in addition to Minimum Inhibitory Concentration (MIC) to gu...
    Medical condition: Periprosthetic hip or knee joint infections
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001207-37 Sponsor Protocol Number: HUB-IDIBELL-SAFO-4.3.1 Start Date*: 2019-04-26
    Sponsor Name:Miquel Pujol i Rojo ( Servicio de Enfermedades Infecciosas del Hospital Universitari de Bellvitge
    Full Title: Phase IV-III Clinical Trial, randomized, controlled, open and multicentric, with parallel groups, to evaluate the efficacy of Cloxacillin and fosfomycin combination versus Cloxacillin monotherapy i...
    Medical condition: Methicilin-susceptible S.aureus bacteraemia.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10058863 Staphylococcus aureus bacteraemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003914-38 Sponsor Protocol Number: 2021-003914-38 Start Date*: 2022-02-14
    Sponsor Name:Fundación Pública Andaluza para la Gestión de la Investigación
    Full Title: Efficacy and safety of different antimicrobial DURATions for the treatment of infections associated with Osteosynthesis Material implanted after long bone fractures (DURATIOM). Phase 4 pragmatic mu...
    Medical condition: Patients with long bone fractures who have had osteosynthesis material implanted to stabilize and assist fracture healing and meet the criteria for Infections associated with osteosynthesis material
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003529-13 Sponsor Protocol Number: 010617 Start Date*: 2017-10-19
    Sponsor Name:Thomas Benfield
    Full Title: Efficacy of seven and fourteen days of antibiotic treatment in uncomplicated Staphylococcus aureus bacterermia: A randomized, non-blinded, non-inferiority interventional study
    Medical condition: Staphylococcus aureus bacteremia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10058887 Staphylococcus aureus bacteremia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-003562-20 Sponsor Protocol Number: 2018-018 Start Date*: 2023-03-07
    Sponsor Name:INSTITUT PASTEUR
    Full Title: A Multicentric Randomized Double-Blind Phase 3 Trial Evaluating the Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Active Hidradenitis Suppurativa Patients versus Tetracycline Derivative
    Medical condition: Hidradenitis Suppurativa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001841-11 Sponsor Protocol Number: MPOH06 Start Date*: 2021-11-09
    Sponsor Name:MaaT Pharma
    Full Title: Evaluation of the efficacy of MaaT013 as salvage therapy in acute GVHD patients with gastrointestinal involvement, refractory to ruxolitinib; a multi-center open-label phase III trial
    Medical condition: Salvage therapy of acute GVHD patients with gastrointestinal involvement, refractory to ruxolitinib.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10066264 Acute graft versus host disease in intestine PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 23 17:34:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA